Interstitial Lung Disease Life Expectancy

Interstitial Lung Disease Life Expectancy

Not all lung diseases are the same. Each person with a chronic lung disease is unique and the challenges they face are different.

Because of this, doctors and pulmonologist use umbrella terms which better describe certain types of lung disease. Interstitial Lung Disease (ILD) is one of those terms. Interstitial lung disease is a progressive lung condition that makes breathing and physical activity increasingly difficult. Simple tasks such as walking to the mailbox or taking a shower may become extremely time and energy-intensive or, eventually, altogether impossible. As many as 12 million people in America suffer from chronic lung disease, the fourth leading cause of death in the United States, according to Healthline.

About Interstitial Lung Disease

The term interstitial lung disease encompasses over 100 different types of pulmonary disorders that affect the ability of the lungs to absorb oxygen, including a diverse collection of illnesses with a variety of causes, treatments and prognoses. Those who suffer from interstitial lung disease often suffer from an acute and constant shortness of breath that can limit daily activities. Interstitial lung disease is often characterized by scarring of the delicate tissues of the lungs and a subsequent dry, annoying cough.

Interstitial lung disease can develop without apparent cause. Such inexplicable cases are referred to as idiopathic. The most common form of idiopathic interstitial lung disease is pulmonary fibrosis. As interstitial lung disease is a progressive disorder, identifying a known cause for the disease is especially important. Because interstitial lung disease can be caused by environmental factors, removing external triggers may slow the progression of the disease and minimize further damage to the lungs. If the disease is idiopathic, stem cell treatment and other forms of regenerative medicine may be beneficial.

Interstitial Lung Disease Life Expectancy

Interstitial Lung Disease Life Expectancy

Unfortunately, due to the progressive nature of interstitial lung disease and the fact there is no known cure, diagnosis can feel like a death sentence. However, exercise, dieting, prescription drugs and stem cell therapy can help to slow, or even arrest the disease. Even with all the factors we know about the disease, no current model exists to predict life expectancy for those with the condition.

Treating Advanced Interstitial Lung Disease

Stem cell therapy for lung disease has been a growing treatment option over the past few years. At the Lung Institute, a progressive stem cell treatment clinic that has emerged as a leader in the global stem cell community, they use stem cells from the patient’s own body to treat lung disease. The cells are called autologous stem cells. These cells are taken intravenously from the patient’s blood (venous stem cells) or bone marrow. The stem cells are then separated and returned to the body through an intravenous drip. The new healthy cells are attracted to the areas of the damaged lung cells and get to work promoting the healing of lung tissue. This results is the ability of the patients to breathe easier and inevitably get their life back.

A progressive lung disease often leads to a patient needing to take their treatment into their own hands through researching various options that may seem non-traditional. Most patients are not ready to simply give up on their health, and unfortunately, the prognosis that comes along with interstitial lung disease can seem like it’s the only option.

If you or a loved one has emphysema, stem cell treatment may be right for you. Contact the Lung Institute for a free consultation or call (800) 729-3065.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. The Lung Institute is firmly in accordance with the conditions set by the FDA for exemption status and conducts itself in full accordance with current guidelines. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.

As required by Texas state law, the Lung Institute Dallas Clinic has received Institutional Review Board (IRB) approval from MaGil IRB, now Chesapeake IRB, which is fully accredited by the Association for the Accreditation of Human Research Protection Program (AAHRPP), for research protocols and stem cell procedures. The Lung Institute has implemented these IRB approved standards at all of its clinics nationwide. Approval indicates that we follow rigorous standards for ethics, quality, and protections for human research.